Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Goldman Adds BHP Billiton To Conviction Buy List

Thu, 15th Jan 2015 09:49

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
GOLDMAN SACHS RAISES BHP BILLITON TO 'CONVICTION BUY LIST' ('NEUTRAL') - PRICE TARGET 1575 (1870) PENCE
----------
NOMURA CUTS BG GROUP PRICE TARGET TO 900 (1000) PENCE - 'REDUCE'
----------
JEFFERIES CUTS BG GROUP PRICE TARGET TO 1215 (1250) PENCE - 'BUY'
----------
NOMURA CUTS BP PRICE TARGET TO 380 (430) PENCE - 'NEUTRAL'
----------
JEFFERIES CUTS BP PRICE TARGET TO 470 (490) PENCE - 'BUY'
----------
JEFFERIES CUTS SHELL A PRICE TARGET TO 2450 (2540) PENCE - 'BUY'
----------
NOMURA CUTS SHELL B PRICE TARGET TO 2350 (2600) PENCE - 'BUY'
----------
S&P CAPITAL IQ CUTS BHP BILLITON TO 'HOLD' ('BUY') - PRICE TARGET 1300 (1825) PENCE
----------
UBS CUTS BHP BILLITON PRICE TARGET TO 1870 (2000) PENCE - 'BUY'
----------
BARCLAYS CUTS BHP BILLITON PRICE TARGET TO 1500 (2100) PENCE - 'OVERWEIGHT'
----------
S&P CAPITAL IQ RAISES BURBERRY PRICE TARGET TO 1520 (1420) PENCE - 'SELL'
----------
TRADERS: NUMIS CUTS ANTOFAGASTA TO 'REDUCE' ('HOLD')
----------
S&P CAPITAL IQ CUTS ANTOFAGASTA TO 'SELL' ('HOLD') - TARGET 625 (760) PENCE
----------
BARCLAYS CUTS ANTOFAGASTA PRICE TARGET TO 700 (745) PENCE - 'EQUAL WEIGHT'
----------
S&P CAPITAL IQ CUTS RIO TINTO PRICE TARGET TO 2800 (3300) PENCE - 'HOLD'
----------
UBS CUTS RIO TINTO PRICE TARGET TO 3300 (3500) PENCE - 'BUY'
----------
BERNSTEIN RAISES RBS PRICE TARGET TO 470 (450) PENCE - 'OUTPERFORM'
----------
BARCLAYS CUTS ANGLO AMERICAN PRICE TARGET TO 1080 (1550) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES FRESNILLO PRICE TARGET TO 835 (800) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES RANDGOLD RESOURCES TARGET TO 5600 (4900) PENCE - 'OVERWEIGHT'
----------
TRADERS: NUMIS CUTS RANDGOLD RESOURCES TO 'HOLD' ('BUY')
----------
BARCLAYS RAISES COMPASS GROUP PRICE TARGET TO 1250 (1180) PENCE - 'OVERWEIGHT'
----------
CS CUTS COMPASS GROUP TO 'NEUTRAL' ('OUTPERFORM') - TARGET 190 PENCE
----------
BARCLAYS RAISES INTERCONTINENTAL HOTELS TARGET TO 2650 (2360) PENCE; 'EQUAL WEIGHT.'
----------
BARCLAYS RAISES WHITBREAD PRICE TARGET TO 5400 (4900) PENCE - 'OVERWEIGHT'
----------
Investec Raises BAT Price Target To 3,600P From 3,400P, Keeps At Hold
----------
EXANE BNP CUTS SKY PLC TO 'NEUTRAL' ('OUTPERFORM') - PRICE TARGET 1000 (985) PENCE
----------
EXANE BNP RAISES GKN PRICE TARGET TO 380 (340) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS SMITHS GROUP PRICE TARGET TO 1050 (1150) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS WEIR GROUP PRICE TARGET TO 1500 (1835) PENCE - 'UNDERPERFORM'
----------
DEUTSCHE BANK RAISES ASTRAZENECA PRICE TARGET TO 4800 (4350) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS GLAXOSMITHKLINE PRICE TARGET TO 1300 (1390) PENCE - 'HOLD'
----------
HSBC RAISES EASYJET PRICE TARGET TO 1500 (1450) PENCE - 'UNDERWEIGHT'
----------
HSBC CUTS ADMIRAL GROUP PRICE TARGET TO 1590 (1625) PENCE - 'OVERWEIGHT'
----------
HSBC CUTS RSA INSURANCE PRICE TARGET TO 474 (480) PENCE - 'NEUTRAL'
----------
HSBC CUTS AVIVA PRICE TARGET TO 535 (590) PENCE - 'NEUTRAL'
----------
HSBC RAISES PRUDENTIAL PRICE TARGET TO 1800 (1725) PENCE - 'OVERWEIGHT'
----------
HSBC RAISES DIRECT LINE PRICE TARGET TO 346 (335) PENCE - 'OVERWEIGHT'
----------
HSBC RAISES FRIENDS LIFE PRICE TARGET TO 420 (415) PENCE - 'OVERWEIGHT'
----------
HSBC RAISES LEGAL & GENERAL PRICE TARGET TO 296 (285) PENCE - 'OVERWEIGHT'
----------
HSBC CUTS STANDARD LIFE PRICE TARGET TO 425 (430) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
JPMORGAN RAISES REDEFINE INTERNATIONAL TARGET TO 53 (50) PENCE - 'UNDERWEIGHT'
----------
BERENBERG INITIATES BODYCOTE WITH 'HOLD' - TARGET 684 PENCE
----------
SOCGEN RAISES PROVIDENT FINANCIAL PRICE TARGET TO 2540 (2270) PENCE - 'HOLD'
----------
TRADERS: NUMIS CUTS KAZ MINERALS TO 'REDUCE' ('HOLD')
----------
BARCLAYS CUTS KAZ MINERALS PRICE TARGET TO 150 (255) PENCE - 'EQUAL WEIGHT'
----------
CREDIT SUISSE RAISES LADBROKES TO 'NEUTRAL' ('UNDERPERFORM') - TARGET 115 PENCE
----------
BARCLAYS CUTS LADBROKES PRICE TARGET TO 104 (126) PENCE - 'EQUAL WEIGHT'
----------
CREDIT SUISSE CUTS DOMINO'S PIZZA TO 'NEUTRAL' ('OUTPERFORM') - TARGET 695 (650) PENCE
----------
TRADERS: CITIGROUP RAISES JUPITER FUND TO 'BUY' ('NEUTRAL')
----------
BARCLAYS CUTS LONMIN PRICE TARGET TO 155 (190) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS RAISES ACACIA MINING TO 'OVERWEIGHT' ('EQUAL WEIGHT')
----------
BARCLAYS CUTS PETRA DIAMONDS PRICE TARGET TO 280 (290) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES POLYMETAL TO 'EQUAL WEIGHT' ('UNDERWEIGHT')
----------
BARCLAYS CUTS VEDANTA PRICE TARGET TO 400 (840) PENCE - 'UNDERWEIGHT'
----------
EXANE BNP RAISES TALK TALK TELECOM TARGET TO 220 (200) PENCE - 'UNDERPERFORM'
----------
BARCLAYS RAISES MERLIN ENTERTAINMENTS TARGET TO 450 (420) PENCE - 'OVERWEIGHT'
----------
BARCLAYS CUTS WILLIAM HILL PRICE TARGET TO 390 (400) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS CUTS MARSTONS TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 130 (150) PENCE
----------
EXANE BNP RAISES HALMA TO 'OUTPERFORM' ('NEUTRAL') - TARGET 780 (685) PENCE
----------
EXANE BNP RAISES ROTORK TO 'NEUTRAL' ('UNDERPERFORM') - TARGET 2300 PENCE
----------
EXANE BNP CUTS SPECTRIS TO 'UNDERPERFORM' ('NEUTRAL') - TARGET 1825 (1740) PENCE
----------
EXANE BNP RAISES SPIRAX-SARCO TO 'NEUTRAL' ('UNDERPERFORM')
----------
EXANE BNP RAISES SPIRAX-SARCO TARGET TO 2935 (2450) PENCE
----------
EXANE BNP RAISES VESUVIUS TO 'OUTPERFORM' ('NEUTRAL') - TARGET 510 (440) PENCE
----------
BARCLAYS RAISES BETFAIR PRICE TARGET TO 1626 (1576) PENCE - 'OVERWEIGHT'
----------
SOCGEN RAISES BBA AVIATION PRICE TARGET TO 400 (360) PENCE - 'BUY'
----------
HSBC CUTS CATLIN GROUP TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 720 (620) PENCE
----------
HSBC CUTS PHOENIX GROUP TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 875 (870) PENCE
----------
HSBC RAISES AMLIN PRICE TARGET TO 433 (420) PENCE - 'UNDERWEIGHT'
----------
HSBC RAISES ESURE GROUP PRICE TARGET TO 330 (320) PENCE - 'OVERWEIGHT'
----------
HSBC RAISES HISCOX PRICE TARGET TO 715 (690) PENCE - 'NEUTRAL'
----------
HSBC RAISES LANCASHIRE HLDGS PRICE TARGET TO 655 (650) PENCE - 'OVERWEIGHT'
----------
MAIN MARKET AND AIM
----------
UBS CUTS FENNER PRICE TARGET TO 210 (235) PENCE - 'NEUTRAL'
----------
UBS CUTS PREMIER OIL PRICE TARGET TO 200 (300) PENCE - 'BUY'
----------
TRADERS: NUMIS CUTS PETROPAVLOVSK TO 'SELL' ('REDUCE')
----------
BARCLAYS CUTS FERREXPO TO 'UNDERWEIGHT' ('EQUAL WEIGHT.') - TARGET 50 (140) PENCE
----------
BARCLAYS CUTS GEM DIAMONDS PRICE TARGET TO 245 (260) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES HOCHSCHILD MINING TO 'OVERWEIGHT' ('EQUAL WEIGHT')
----------
PANMURE RAISES SQS SOFTWARE PRICE TARGET TO 590 (527) PENCE - 'HOLD'
----------
HSBC RAISES FLYBE GROUP PRICE TARGET TO 150 (140) PENCE - 'OVERWEIGHT'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.